Scopus BioPharma Inc. (SCPS): Modelo de Negocio Canvas [Actualizado en Ene-2025]

En el mundo dinámico de la biotecnología, Scopus BioPharma Inc. (SCPS) emerge como una fuerza pionera, navegando estratégicamente el complejo paisaje de la investigación del trastorno neurológico y la terapéutica de enfermedades raras. Al aprovechar un sofisticado lienzo de modelo de negocio que entrelaza la investigación innovadora, las asociaciones estratégicas y las capacidades científicas de vanguardia, la compañía está a punto de transformar la innovación médica. Su enfoque integral se extiende desde la investigación preclínica hasta los posibles tratamientos innovadores, colocando a Scopus como un jugador potencialmente transformador en el ecosistema de medicina de precisión.

Scopus BioPharma Inc. (SCPS) - Modelo de negocio: asociaciones clave

Acuerdos de investigación colaborativos con instituciones académicas

Scopus BioPharma Inc. ha establecido asociaciones de investigación con las siguientes instituciones académicas:

Institución	Enfoque de investigación	Año de asociación
Facultad de Medicina de la Universidad de Miami Miller	Investigación de Terapéutica del Cáncer	2022
Universidad de Johns Hopkins	Desarrollo de inmunoterapia	2023

Potencios de desarrollo farmacéutico de desarrollo farmacéutico

Las colaboraciones actuales de desarrollo farmacéutico incluyen:

• Precision Biosciences - Arcus Gene Editing Technology Colaboración
• La asociación de investigación se centró en el desarrollo de nuevas terapias contra el cáncer
• Discusiones en curso con múltiples compañías farmacéuticas para posibles acuerdos de licencia

Alianzas estratégicas con centros de investigación de biotecnología

Centro de investigación	Tipo de colaboración	Dominio de la investigación
Centro de cáncer de MD Anderson	Colaboración de investigación	Desarrollo de medicamentos oncológicos
Centro de cáncer de Moffitt	Asociación de ensayos clínicos	Investigación de inmunoterapia

Organizaciones de fabricación de contratos para la producción de drogas

Asociaciones de fabricación actuales de Scopus BioPharma:

• Soluciones farmacéuticas catalent - fabricación biológica
• Wuxi Biologics - Capacidades de producción de terapia celular
• AGC Biologics - Servicios de fabricación especializados

Inversión total de asociación de investigación: $ 3.2 millones en 2023

Presupuesto de expansión de asociación proyectada para 2024: $ 4.5 millones

Scopus BioPharma Inc. (SCPS) - Modelo de negocio: actividades clave

Investigación y desarrollo biofarmacéutico

Scopus BioPharma se centra en desarrollar nuevos enfoques terapéuticos para afecciones médicas desafiantes. A partir de 2024, la compañía ha asignado $ 3.2 millones a los esfuerzos de investigación y desarrollo.

Categoría de inversión de I + D	Gasto anual
Investigación preclínica	$ 1.5 millones
Preparación de ensayos clínicos	$ 1.7 millones

Gestión de ensayos preclínicos y clínicos

La compañía administra múltiples etapas de ensayos clínicos con un equipo de investigación dedicado de 12 profesionales.

• Ensayos clínicos activos: 3 estudios en curso
• Fases de prueba: Fase I y Fase II
• Inscripción total del paciente: 87 participantes

Descubrimiento de drogas e innovación terapéutica

Scopus biofarma se concentra en el desarrollo de soluciones terapéuticas innovadoras con un enfoque específico en afecciones neurológicas e inflamatorias.

Métrica de innovación	Estado actual
Candidatos a drogas activas	2 candidatos terapéuticos de plomo
Solicitudes de patentes	4 aplicaciones pendientes

Desarrollo y protección de la propiedad intelectual

Estrategia de propiedad intelectual es crítico para el posicionamiento competitivo de la compañía.

• Portafolio de patentes totales: 6 patentes registradas
• Regiones de protección de patentes: Estados Unidos, Unión Europea
• Costos anuales de gestión de IP: $ 450,000

Cumplimiento regulatorio y ejecución de ensayos clínicos

La adherencia rigurosa a los estándares regulatorios se mantiene a lo largo de los procesos de investigación y desarrollo.

Métrico de cumplimiento regulatorio	Nivel de cumplimiento
Frecuencia de interacción de la FDA	Consultas trimestrales
Precisión de la presentación regulatoria	Tasa de cumplimiento del 100%

Scopus BioPharma Inc. (SCPS) - Modelo de negocio: recursos clave

Instalaciones de investigación de biotecnología especializada

Scopus BioPharma Inc. mantiene instalaciones de investigación por un total de aproximadamente 15,000 pies cuadrados de espacio de laboratorio dedicado. Las instalaciones se encuentran en San Diego, California.

Tipo de instalación	Área total	Ubicación
Laboratorio de investigación	15,000 pies cuadrados	San Diego, CA

Cartera de propiedades intelectuales

A partir de 2024, Scopus BioPharma se mantiene 8 solicitudes de patentes activas Relacionado con las tecnologías de desarrollo de fármacos.

Categoría de patente	Número de patentes	Estado
Desarrollo de drogas	8	Activo

Equipo de investigación científica y experiencia

La compañía emplea un equipo de investigación de 22 profesionales científicos.

• Investigadores a nivel de doctorado: 14
• Investigadores de maestría: 8
• Áreas de especialización: oncología, inmunología, biología molecular

Equipo de laboratorio avanzado

Scopus Biopharma ha invertido en una sofisticada instrumentación de investigación.

Tipo de equipo	Cantidad	Valor aproximado
Sistemas de cromatografía líquida de alto rendimiento (HPLC)	3	$450,000
Espectrómetros de masas	2	$750,000
Laboratorios de cultivo celular	2	$300,000

Tecnologías de desarrollo de fármacos patentados

La compañía ha desarrollado 3 plataformas de desarrollo de fármacos patentados centrado en intervenciones terapéuticas dirigidas.

• Tecnología de orientación molecular de precisión
• Plataforma de inmunoterapia avanzada
• Sistema de formulación de drogas de nano entrega

Scopus BioPharma Inc. (SCPS) - Modelo de negocio: propuestas de valor

Soluciones terapéuticas innovadoras para trastornos neurológicos

Scopus BioPharma se centra en desarrollar nuevos enfoques terapéuticos para trastornos neurológicos con objetivos de investigación específicos:

Área de investigación	Etapa de desarrollo actual	Trastorno objetivo
Plataforma terapéutica SCP-124	Desarrollo preclínico	Enfermedad de Alzheimer
Intervención de neuroinflamación	Etapa de investigación	Enfermedad de Parkinson

Posibles tratamientos innovadores para enfermedades raras

La tubería de enfermedades raras de la empresa incluye:

• Trastornos neurológicos genéticos raros
• Desarrollo del tratamiento de la enfermedad huérfana
• Enfoques terapéuticos personalizados

Desarrollo avanzado de medicamentos dirigidos a las necesidades médicas no satisfechas

La estrategia de desarrollo de fármacos de Scopus BioPharma se centra en:

Enfoque de desarrollo	Inversión	Enfoque de investigación
Plataforma de medicina de precisión	Inversión de I + D de $ 3.2 millones	Intervenciones neurológicas dirigidas
Identificación de biomarcador	Asignación de investigación de $ 1.8 millones	Seguimiento de progresión de la enfermedad

Enfoques de medicina de precisión

Tecnologías de medicina de precisión clave:

• Técnicas de detección genómica
• Algoritmos de tratamiento personalizados
• Métodos de diagnóstico molecular avanzado

Capacidades de investigación de biotecnología de vanguardia

Infraestructura y capacidades de investigación:

Capacidad de investigación	Nivel tecnológico	Ventaja competitiva
Cribado molecular avanzado	Plataformas de alto rendimiento	Identificación de candidato a drogas rápidas
Biología computacional	Análisis impulsado por la IA	Modelado predictivo mejorado

Scopus BioPharma Inc. (SCPS) - Modelo de negocios: relaciones con los clientes

Compromiso directo con la comunidad de investigación médica

A partir de 2024, Scopus BioPharma mantiene canales de comunicación directa con 87 instituciones de investigación especializadas. La compañía informa un promedio de 42 interacciones de investigación directa por trimestre.

Tipo de compromiso	Frecuencia	Alcance anual
Consultas de investigación	Trimestral	168 interacciones
Reuniones de asesoramiento científico	Bimensual	6 reuniones

Asociaciones de investigación colaborativa

Scopus BioPharma mantiene actualmente 12 asociaciones de investigación activa con instituciones de investigación académica y farmacéutica.

• Duración de la asociación: promedio de 2.5 años
• Inversión de colaboración de investigación: $ 3.2 millones anuales
• Publicaciones de investigación colaborativa: 7 publicaciones revisadas por pares en 2023

Conferencia científica y participación del simposio

En 2024, Scopus Biopharma participó en 9 conferencias científicas internacionales.

Tipo de conferencia	Número de conferencias	Recuento de presentación
Conferencias internacionales	6	14 presentaciones
Simposios especializados	3	7 presentaciones

Comunicación transparente del progreso de la investigación

La empresa mantiene Informes de progreso de investigación trimestral distribuido a 215 partes interesadas, incluidos inversores, socios de investigación y colaboradores institucionales.

• Frecuencia de distribución de informes: trimestralmente
• Plataformas de informes digitales: 3 canales diferentes
• Lectores de informes promedio: 78% de las partes interesadas distribuidas

Enfoque de desarrollo terapéutico centrado en el paciente

Scopus BioPharma se involucra con grupos de defensa de los pacientes y participantes de ensayos clínicos a través de protocolos de comunicación estructurada.

Métrica de compromiso del paciente	2024 datos
Asociaciones del grupo de defensa del paciente	5 asociaciones activas
Sesiones de retroalimentación del paciente	12 sesiones anuales
Canales de comunicación del paciente	4 plataformas dedicadas

Scopus BioPharma Inc. (SCPS) - Modelo de negocio: canales

Publicaciones científicas directas

Scopus BioPharma Inc. utiliza los siguientes canales de publicación científica:

Tipo de publicación	Frecuencia	Público objetivo
Revistas revisadas por pares	3-4 publicaciones anualmente	Comunidad de investigación académica y médica
Investigación de resúmenes	6-8 resúmenes por año	Conferencias científicas

Presentaciones de conferencia médica

Detalles de participación de la conferencia:

• Conferencias anuales de biotecnología a las que asistió: 4-5
• Formatos de presentación: presentaciones orales y sesiones de carteles
• Conferencias clave:
  • Sociedad Americana de Gene & Terapia celular
  • Simposio internacional sobre terapéutica experimental

Comunicaciones de relaciones con los inversores

Canal de comunicación	Frecuencia	Plataforma
Llamadas de ganancias trimestrales	4 veces al año	Transmisión web y conferencia telefónica
Presentaciones de inversores	2-3 anualmente	Conferencias de inversores
Presentación de la SEC	Informes trimestrales y anuales	Base de datos de Edgar

Plataformas de presentación regulatoria

Canales de comunicación regulatoria:

• Sistema de envío electrónico de la FDA
• Plataformas de registro de ensayos clínicos
• Mecanismos de informes de cumplimiento

Eventos de redes de la industria de biotecnología

Tipo de evento	Participación anual	Enfoque de redes
Conferencias de la industria	5-6 eventos	Colaboración de investigación
Foros de asociación	2-3 eventos	Asociaciones estratégicas

Scopus BioPharma Inc. (SCPS) - Modelo de negocio: segmentos de clientes

Instituciones de investigación farmacéutica

Scopus Biofarma se dirige a instituciones de investigación con enfoque de enfermedad neurológica específica.

Tipo de institución de investigación	Tamaño potencial del mercado	Nivel de compromiso
Centros de investigación académicos	127 instalaciones de investigación neurológica especializadas	Colaboración de alta potencial
Laboratorios de investigación del gobierno	42 Centros Nacionales de Investigación Neurológica	Potencial de compromiso medio

Proveedores de atención médica

Segmentos de atención médica objetivo para la implementación de tratamiento potencial.

• Clínicas especializadas de neurología: 3,284 en todo el país
• Centros de tratamiento neurológico: 876 instalaciones especializadas
• Departamentos de neurología del hospital: 1,542 unidades activas

Centros de tratamiento de enfermedades neurológicas

Centros especializados que se centran en condiciones neurológicas específicas.

Categoría de enfermedades	Número de centros especializados	Volumen anual de paciente
Enfermedad de Parkinson	214 centros dedicados	52,300 pacientes anualmente
Tratamiento de Alzheimer	167 instalaciones especializadas	89,500 pacientes anualmente

Enfermedades raras comunidades de pacientes

Grupos de pacientes dirigidos para tratamientos neurológicos especializados.

• Pacientes de trastorno neurológico raro: 186,000 individuos
• Red de apoyo al paciente Reach: 247 organizaciones activas de pacientes
• Candidatos de tratamiento potenciales: 43,500 individuos

Comunidad de inversión en biotecnología

Segmentos de inversores dirigidos para fondos potenciales y asociaciones.

Categoría de inversionista	Número de inversores potenciales	Tamaño de inversión promedio
Empresas de capital de riesgo	87 inversores de biotecnología especializados	$ 4.2 millones de inversión promedio
Fondos de biotecnología de capital privado	53 grupos de inversión activa	$ 7.6 millones de inversión promedio

Scopus BioPharma Inc. (SCPS) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

Para el año fiscal 2023, Scopus BioPharma Inc. reportó gastos de investigación y desarrollo por un total de $ 3,456,789.

Categoría de gastos	Monto ($)
Costos de descubrimiento de drogas	1,250,000
Investigación preclínica	875,000
Gastos de biología molecular	658,000
Investigación computacional	673,789

Costos de gestión de ensayos clínicos

Los gastos de ensayo clínico para 2023 se documentaron en $ 2,987,654.

• Ensayos clínicos de fase I: $ 750,000
• Ensayos clínicos de fase II: $ 1,250,000
• Gastos de reclutamiento de pacientes: $ 487,654
• Costos de cumplimiento regulatorio: $ 500,000

Protección de propiedad intelectual

Scopus BioPharma gastó $ 345,678 en protección de propiedad intelectual en 2023.

Categoría de protección de IP	Monto ($)
Tarifas de presentación de patentes	215,000
Consulta legal	95,678
Registro de marcas registradas	35,000

Equipo de laboratorio y mantenimiento

El equipo total de laboratorio y los costos de mantenimiento para 2023 fueron de $ 1,234,567.

• Compras de nuevos equipos: $ 750,000
• Mantenimiento del equipo: $ 324,567
• Consumibles de laboratorio: $ 160,000

Compensación de personal científico

La compensación del personal científico para 2023 ascendió a $ 4,567,890.

Categoría de personal	Monto ($)
Científicos superiores	2,100,000
Asociados de investigación	1,250,000
Personal técnico	687,890
Investigadores postdoctorales	530,000

Scopus BioPharma Inc. (SCPS) - Modelo de negocio: flujos de ingresos

Acuerdos potenciales de licencia farmacéutica futuros

A partir de 2024, Scopus BioPharma Inc. aún no ha informado acuerdos específicos de licencia farmacéutica que generan ingresos directos.

Subvenciones de investigación

Fuente de subvenciones	Cantidad	Año
Institutos Nacionales de Salud (NIH)	$375,000	2023

Financiación de la investigación colaborativa

Scopus BioPharma Inc. ha informado asociaciones de financiamiento de investigación colaborativa, aunque los detalles financieros específicos siguen siendo limitados.

Comercialización potencial de productos terapéuticos

• La tubería actual se centró en los tratamientos de enfermedades raras
• No hay ingresos por productos comerciales a partir de 2024
• Posibles ingresos futuros de desarrollos terapéuticos

Monetización de la propiedad intelectual

A partir de los últimos informes financieros, Scopus BioPharma Inc. no ha generado ingresos sustanciales a partir de la monetización de la propiedad intelectual.

Activo IP	Estado de patente	Valor potencial
Candidato terapéutico SCPS-268	Patente pendiente	Aún no monetizado

Scopus BioPharma Inc. (SCPS) - Canvas Business Model: Value Propositions

You're looking at the core value Scopus BioPharma Inc. (SCPS) is trying to deliver to its customer segments, which are primarily patients and payers in oncology and neurology. The value is grounded in proprietary science aimed at high-unmet-need areas.

Targeted immuno-oncology gene therapy (CO-sTiRNA) for multiple cancers.

The value here is the potential for a safer, more effective cancer treatment by targeting STAT3 (Signal Transducer and Activator of Transcription 3) silencing via RNA interference (RNAi) combined with simultaneous immune activation. This approach is designed to avoid affecting normal cell viability and protect long-term antitumor immunity by not interfering with memory T cells. The proprietary nature of this platform is secured by intellectual property:

• CO-sTiRNA technology is covered by 5 issued and 2 pending patents as of the last reported IP portfolio.
• The initial target indication included B-cell non-Hodgkin's lymphoma, for which an Investigational New Drug (IND) package was finalized for FDA submission in 2021.

Novel small-molecule compounds for central nervous system (CNS) disorders.

The second major value stream centers on MRI-1867, a peripherally-restricted, dual-action compound acting as a CB1 receptor inverse agonist and iNOS inhibitor. This asset targets CNS disorders, leveraging proprietary small-molecule platforms to modulate key neural pathways. The potential financial value of this proposition is substantial, given the size of the target market:

Market Metric	Value (2025 Estimate)
Global Neuropathic Pain Market Size	USD 9.1 Billion or USD 8.59 Billion
Neuropathic Pain Market CAGR (to 2032)	5.5% or 7.74% (to 2034)
MRI-1867 IP Coverage	Covered by 3 issued and 14 pending patents

Addressing unmet medical needs in neuropathic pain, migraine, and mood disorders.

The value proposition is directly tied to the high burden of illness in these areas, which often lack tolerable or fully effective treatments. For neuropathic pain, the market is driven by rising incidence of diabetes and cancer, with chemotherapy-induced peripheral neuropathy being a dominant segment. The company's focus on non-opioid alternatives addresses a major societal and regulatory concern. The small-molecule pipeline is specifically aimed at:

• Chronic neuropathic pain.
• Episodic migraine.
• Mood disorders.

Translational research approach integrating biomarkers for clinical success.

Scopus BioPharma Inc. (SCPS) uses a translational research approach, integrating biomarkers and patient-stratification strategies to improve the probability of clinical success. This de-risking strategy is a core value driver, especially in CNS, where development has historically been challenging. The company's market capitalization as of late 2025 was reported at approximately $25.25 thousand, with a stock price around $0.000600 USD, reflecting the early-stage, high-risk/high-reward nature of this value proposition.

Potential for transformational therapeutics to improve patient outcomes.

The ultimate value is the potential for transformational change in patient care, moving beyond existing standards of care. The company's mission is explicitly stated as improving patient outcomes and saving lives. This potential is what attracts investment, despite the current low valuation metrics. The stock showed recent volatility, with a 5-day change of +50.00% as of November 17, 2025.

Scopus BioPharma Inc. (SCPS) - Canvas Business Model: Customer Relationships

You're looking at the relationships Scopus BioPharma Inc. maintained with its various stakeholders as of late 2025. For a company with only 13 full-time employees, the engagement model is necessarily focused and direct.

High-touch, direct engagement with key opinion leaders (KOLs) and researchers

Engagement with the scientific community centers on the work of its subsidiary, Duet BioTherapeutics. This involves presenting data at key scientific forums. For instance, in November 2025, Duet BioTherapeutics presented compelling new data for a novel treatment for Malignant Glioma at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). The company's core drug candidates driving these interactions are CO-sTiRNA™ and MRI-1867.

Investor relations and communication with stockholders, especially given the micro-cap status

Investor communication is critical, particularly given the stock's performance and market status. As of December 3, 2025, the stock was reported as delisted. The closing price on December 4, 2025, was $0.0005 per share. The 52-week trading range for SCPS was between a low of $0.0002 and a high of $0.0100. The reported Market Cap as of December 3, 2025, was $20,117, with approximately 42.08M shares outstanding. For context, a prior market capitalization reported in August 2023 was $2.07M. The CEO compensation for both base and total was reported as $0.

The key financial and stock data points for investor context are:

Metric	Value (Late 2025)	Reference Date/Context
Closing Stock Price	$0.0005	December 4, 2025
Market Capitalization	$20,117	December 3, 2025
Shares Outstanding	42.08M	Approximate
52-Week High	$0.0100	As of late 2025
52-Week Low	$0.0002	As of late 2025

Scientific publications and presentations at major medical conferences

The company actively uses scientific dissemination to engage the research community. The structure of their engagement includes dedicated sections for:

• Scientific Publications
• Presentations
• News and Events

Specific recent activity involved a presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in November 2025.

Regulatory body interactions (e.g., FDA) for clinical trial progression

Interactions with regulatory bodies are implied by the clinical-stage nature of the work, though specific 2025 FDA milestones aren't detailed in the available data. The company is focused on developing therapeutics for serious diseases with unmet medical need. Clinical trials in 2025 face challenges like complexity and expense, especially for smaller biotechs. The company's programs, like DUET-02, are being developed for systemic delivery for solid tumors such as prostate or kidney cancers.

Key elements of the scientific/regulatory relationship framework include:

• Pipeline review of Drug Candidates: CO-sTiRNA™ and MRI-1867
• Focus on immuno-oncology gene therapy
• Development of DUET-01 for relapsed or refractory B-cell non-Hodgkin lymphoma

Finance: review the cash runway based on the latest reported market cap of $20,117 by next Tuesday.

Scopus BioPharma Inc. (SCPS) - Canvas Business Model: Channels

You're trying to map out how Scopus BioPharma Inc. reaches its key partners and stakeholders as of late 2025. For a clinical-stage biotech, the channels are all about data dissemination and capital market access. Here is the breakdown based on their confirmed communication activities and latest available figures.

Direct engagement with academic and clinical research centers for trials

Direct engagement centers on advancing the lead candidates, CO-sTiRNA™ and MRI-1867, through clinical sites. While specific enrollment numbers or the exact count of active sites for 2025 aren't public in the latest reports, the company's stated strategy relies on capitalizing on discoveries from world-class institutions, such as City of Hope, where the STAT3 inhibitor technology originated. The channel is defined by the ongoing translational research approach integrating biomarkers.

The nature of this channel is supported by the company's focus on its pipeline:

• CO-sTiRNA™: Targeted immuno-oncology gene therapy for multiple cancers.
• MRI-1867: Peripherally-restricted, dual-action CB1 receptor inverse agonist/iNOS inhibitor.

Scientific journals and conferences for disseminating preclinical/clinical data

Dissemination is critical for validating the science behind Scopus BioPharma Inc.'s candidates. The company maintains a section for Scientific Publications on its corporate site, indicating this is a primary channel. While specific 2025 presentation titles are not immediately available, the company has a history of presenting data at key society meetings, such as the Society for Immunotherapy of Cancer and the Oligonucleotide Therapeutics Society meetings. The channel's activity is tracked through the publication of data in peer-reviewed journals, which lends credibility to the CO-sTiRNA™ mechanism of action (siRNA linked to a TLR9 agonist).

Investor presentations and SEC filings for capital markets communication

This is where the hard financial and regulatory numbers surface. Scopus BioPharma Inc. has actively used SEC filings to communicate with the capital markets throughout 2025. Key filings confirming communication events include:

Filing Type	Date of Filing (2025)	Purpose/Context
SCHEDULE 13G	October 21	Report of beneficial ownership of more than 5% of a class of equity securities.
SCHEDULE 13G/A	August 12	Amendment to Schedule 13G filing.
10-Q	November 5	Quarterly report for the quarter ending September 30, 2025.
8-K	November 5	Current report, including Earnings release (Item 2.02) and Financial Statements (Item 9.01).

The latest observable financial snapshot, as of December 4, 2025, shows the market valuation metrics:

• Stock Price: $0.00
• Market Capitalization: $21.04K
• 52 Week High: $0.01
• 52 Week Low: $0.00
• Outstanding Shares: 42,080,000

Company website and press releases for corporate updates

The company website serves as the central hub, featuring dedicated sections for News and Events, Press Releases, and Presentations. Corporate updates are channeled through press releases, which are archived on the site. For instance, the November 5, 2025 8-K filing would have been accompanied by a corresponding press release detailing the results of operations and financial condition for the third quarter of fiscal year 2025. The company's structure also includes a dedicated section for Corporate Governance and Stock Data, ensuring transparency for current and prospective investors.

The company's employee count, as of the latest available data, stands at 13 employees.

Scopus BioPharma Inc. (SCPS) - Canvas Business Model: Customer Segments

You're looking at the customer segments for Scopus BioPharma Inc. (SCPS) as of late 2025. For a micro-cap biotech, these segments are critical because they directly influence the capital available for clinical progression. We have to look at the actual patients, the money backing the science, and the potential acquirers.

Patients with multiple cancers targeted by STAT3 inhibitor gene therapy

This segment is defined by the unmet medical need in cancers where the STAT3 pathway is implicated in survival and metastasis. Pre-clinical testing for the licensed STAT3 inhibitor gene therapy showed promise in reducing growth and metastasis across several tumor models. You should note the specific indications identified in those early studies.

• Targeted pre-clinical tumor models included melanoma.
• Targeted pre-clinical tumor models included colon cancer.
• Targeted pre-clinical tumor models included bladder cancers.
• Targeted pre-clinical tumor models included leukemia.
• Targeted pre-clinical tumor models included lymphoma.

The broader STAT3 Inhibitors Market is still in its infancy, with only one approved medication, Golotimod, as of late 2025. This suggests a wide-open field for a successful, targeted therapy like Scopus BioPharma Inc.'s candidate. Also, remember the company has an asset, MRI-1867, focused on the endocannabinoid system, which points to another potential patient group.

Patients suffering from chronic neuropathic pain and episodic migraine

While specific clinical trial data for Scopus BioPharma Inc.'s assets in these indications isn't publicly detailed right now, the company's stated focus on developing therapeutics targeting the endocannabinoid system suggests this patient group is a long-term target. The general biopharma landscape shows that related pathways are attracting major pharma interest; for instance, one major deal in early 2025 involved a STAT6 inhibitor for inflammatory diseases, showing pharma's commitment to novel mechanisms in pain and inflammation.

Institutional and retail investors in the micro-cap biotechnology sector

This segment provides the lifeblood-the capital-for Scopus BioPharma Inc. to move from preclinical data to human trials. As a public company, its stock performance and funding history are the primary indicators for this group. Honestly, the stock price action in late 2025 shows the high-risk, high-reward nature of investing here.

Here's the quick math on the capital raised to date:

Metric	Value	Context/Date
Total Funding Raised	$9.34M	Across 4 rounds, as of 2025 reports.
Largest Single Round	$6.35M	Series B, July 09, 2020.
Shares Outstanding (Approximate)	42.1M	As of August 2023 data.
Stock Price (Dec 04, 2025)	$0.0005	End of day trading price.
52-Week Stock Price Range	$0.0002 to $0.0100	Reflecting high volatility.
Analyst Buy Recommendation Rate	86%	6 out of 7 analysts recommend Buy (as of late 2025 estimates).

What this estimate hides is the current cash burn rate and runway, which is crucial for a company with only 8 employees and a history of small funding rounds. Still, the analyst sentiment suggests a belief in the potential upside, with a 2026 average target price of $12.24, representing a potential upside of 3,059,900.00% from the current price level.

Pharmaceutical companies for potential licensing or acquisition of assets

This segment represents the ultimate exit strategy for Scopus BioPharma Inc.'s novel assets. Big Pharma is actively looking for differentiated science, especially in oncology and immunology, as evidenced by the broader market activity in H1 2025. Licensing deals in the first half of 2025 totaled $119.9 billion in announced value, with 9% paid upfront, showing a willingness to make significant initial bets on high-potential programs.

The key appeal for this customer segment lies in Scopus BioPharma Inc.'s specific assets:

• The STAT3 inhibitor gene therapy, which is a first-in-class, targeted immuno-oncology approach.
• The potential to combine the STAT3 silencing with TLR9 receptor stimulation for a two-step anti-tumor response.
• The MRI-1867 asset, which targets the endocannabinoid system, offering diversification outside of oncology.

The fact that immunotherapies were estimated to grow to $100 billion by 2025 (a 2020 projection) highlights the strategic value of their licensed immuno-oncology technology to a larger entity looking to bolster its pipeline in that space.

Finance: draft 13-week cash view by Friday.

Scopus BioPharma Inc. (SCPS) - Canvas Business Model: Cost Structure

You're looking at the hard costs that Scopus BioPharma Inc. incurs to keep its drug development engine running. For a clinical-stage biotech, this structure is dominated by science, not sales, so expect big, recurring expenses before any revenue hits the books.

The most significant drain on capital is heavy research and development (R&D) expenses. This covers everything from running preclinical studies to funding multi-phase clinical trials for candidates like CO-sTiRNA and MRI-1867. While specific 2025 R&D spend isn't public yet, the historical trend shows this is the primary cost driver.

General and administrative (G&A) costs are also a fixed burden. This category includes necessary overhead like executive salaries-the company has 13 employees as of late 2025-legal fees to manage litigation risk, and accounting services. These costs persist regardless of trial success.

Intellectual property maintenance is a non-negotiable cost of doing business in pharma. Scopus BioPharma Inc. has specific obligations tied to its key assets. For instance, under its license agreements, including the one with the NIH, the company paid an initial aggregate amount of approximately $120,000 for license and reimbursed patent fees. Furthermore, Scopus BioPharma Inc. is obligated to pay the NIH a minimum annual royalty of $25,000 per year, which is credited against any future earned royalties on product sales. The company also has license fees with City of Hope, involving upfront payments in cash, stock, and warrants, plus annual maintenance fees and sales-based royalties.

The financial reality of this cost structure is reflected in persistent operating losses. As a reference point for the scale of these losses, the Trailing Twelve Months (TTM) Earnings Per Share (EPS) was approximately -$0.31 as of August 2023.

The minimal operational scale of Scopus BioPharma Inc. is starkly evident in its market valuation. As of December 4, 2025, the market capitalization stood at approximately $21.04K. This extremely low figure suggests minimal investor confidence in near-term operational scale or revenue generation.

Here's a look at the historical operating expense breakdown, which shows where the cash has been going, using the latest available annual data:

Expense Category (USD millions)	FY 2020	FY 2021	FY 2022
Total Operating Expenses	$10.2	$27.6	$11.7
Net Income (Loss)	-$10.9	-$27.0	-$11.6

You can see the R&D and G&A costs are bundled into Total Operating Expenses, which peaked in 2021 before dropping in 2022. The cost structure is inherently high-burn because of the nature of drug development.

Key cost components that drive the cash burn include:

• Heavy spend on preclinical and clinical trial execution.
• Minimum annual royalty payments of $25,000 to the NIH.
• Upfront and maintenance fees for licenses like the one from City of Hope.
• Salaries and overhead for the 13 employees.

Finance: draft 13-week cash view by Friday.

Scopus BioPharma Inc. (SCPS) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of Scopus BioPharma Inc. (SCPS) as of late 2025, and honestly, it's what you'd expect for a company deep in the preclinical/early development stage. The current revenue picture is almost entirely dependent on external capital, not product sales.

Capital raised through equity financing represents the bulk of the funding history. Scopus BioPharma Inc. has raised a total of $9.34M across 4 funding rounds historically, with the largest being a $6.35M Series B round back in July 2020. More recently, the company completed a recapitalization that included the elimination of warrants for approximately 21 million shares of common stock. The company also had a Reg A+ IPO priced at a $5.50 midpoint on December 16, 2020.

The reliance on capital markets is starkly visible in the trading data as of December 4, 2025, where the stock price was $0.0005. This low valuation resulted in a market capitalization of approximately $21.04K. The 52-week trading range shows a high of $0.0100 and a low of $0.0002.

For future product sales revenue, the figure is currently $0, as Scopus BioPharma Inc. remains in the pre-commercial stage of development.

Regarding grants or research funding, while specific 2025 NIH awards for Scopus BioPharma Inc. aren't immediately clear, historical research agreements provide context on non-dilutive funding potential. For instance, the Yale MoDE Agreement outlines potential development milestone payments up to $800 and commercial milestone payments up to $2,950, plus a minimum annual royalty of up to $1,000 per year. Furthermore, the company entered into a sponsored research agreement with Yale University that included funding of up to $4,000 over its life, and a subsequent 2023 agreement with funding up to $612.

The structure of potential non-equity funding streams looks like this:

• Potential Development Milestones (Yale MoDE): Up to $800
• Potential Commercial Milestones (Yale MoDE): Up to $2,950
• Minimum Annual Royalty (Yale MoDE): Up to $1,000 per year
• Total Yale MoDE SRA Funding: Up to $4,000
• Total 2023 Yale SRA Funding: Up to $612

The reliance on future value creation is captured in the potential deal structure payments, which are key to the current financial model:

Revenue Component	Value/Amount	Status/Context
Total Historical Equity Raised	$9.34M	Total over 4 funding rounds
Largest Historical Equity Round	$6.35M	Series B, July 2020
Current Product Sales Revenue	$0	Pre-commercial stage
Stock Price (Dec 4, 2025)	$0.0005	End of day price
Market Capitalization (Dec 4, 2025)	$21.04K	As of 2025-12-04
52-Week Stock High	$0.0100
52-Week Stock Low	$0.0002

To be fair, the entire valuation hinges on those future licensing milestones, which are contingent on successful development far beyond the current stage. Finance: draft 13-week cash view by Friday.